Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.60    -0.10 (-3.70%)
Bid:
2.50
Ask:
2.60
Spread: 0.10 (4.00%)
Market Cap: £2.68m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Directorate Change

19 Dec 2024 07:00

RNS Number : 6217Q
Litigation Capital Management Ltd
19 December 2024
 

19 December 2024

Litigation Capital Management Limited

("LCM" or the "Company")

Directorate Change

 

Litigation Capital Management Limited (AIM:LIT), a leading international alternative asset manager of disputes financing solutions, announces that Gerhard Seebacher has notified the Company that he is stepping down from his role as a Non-Executive Director of the Company. Gerhard's decision comes as a result of being appointed to a senior position at Jain Global, a recently launched global hedge fund, which precludes him from serving on the boards of publicly listed companies. Gerhard will formally step down on 15 January 2025.

The Nominations Committee of the LCM Board is well advanced in selecting a new Non-Executive who will bring relevant skills and experience to the Company's expansion and scale. The Company expects to be in a position to announce the new Board Member in the first quarter of 2025.

Jonathan Moulds, Chairman of LCM, commented: "On behalf of the Board and the entire team at LCM, I would like to express my sincere gratitude to Gerhard for his valuable contributions during his tenure. His insight, experience, and commitment have been instrumental in guiding the Company through an important phase of its growth. We wish him every success in his new role."

Gerhard Seebacher commented: "It has been a privilege to serve as a Non-Executive Director of LCM and to work with such a talented and dedicated team. While I am stepping down due to my new commitments, I remain a firm supporter of LCM and its future prospects. I wish the Board and the team continued success as they build on the Company's strong foundation."

Enquiries

Litigation Capital Management

c/o Tavistock PR

Patrick Moloney, Chief Executive Officer

David Collins, Chief Financial Officer

Cavendish (Nomad and Joint Broker) 

Tel: 020 7220 0500

Jonny Franklin-Adams and Rory Sale (Corporate Finance)

Tim Redfern and Jamie Anderson (Corporate Broking)

Canaccord Genuity (Joint Broker)

Tel: 020 7523 8000

Bobbie Hilliam

Tavistock PR

Tel: 020 7920 3150

Katie Hopkins

Simon Hudson

lcm@tavistock.co.uk

 

NOTES TO EDITORS

Litigation Capital Management (LCM) is an alternative asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record driven by disciplined project selection and robust risk management.

Currently headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

www.lcmfinance.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGPGBAPUPCGPR
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.